Pharsight

Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6758214 VERO BIOTECH INC Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
Feb, 2022

(2 years ago)

US8609028 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US9956373 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US11554241 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US9522249 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US8226916 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US10124142 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US11383059 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US11291793 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US8821801 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 2 months from now)

US10814092 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2025

(1 year, 4 months from now)

US8057742 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2026

(1 year, 7 months from now)

US7618594 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(2 years from now)

US7947227 VERO BIOTECH INC Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(2 years from now)

US7560076 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Apr, 2027

(2 years from now)

US9701538 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2029

(4 years from now)

US9604028 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US8944049 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US10926054 VERO BIOTECH INC Systems and devices for generating nitric oxide
Aug, 2029

(5 years from now)

US11511252 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Sep, 2029

(5 years from now)

US11103669 VERO BIOTECH INC Nitric oxide therapies
Jun, 2030

(6 years from now)

US8607785 VERO BIOTECH INC Systems and devices for generating nitric oxide
Jul, 2030

(6 years from now)

US10737051 VERO BIOTECH INC Nitrogen dioxide storage device
Oct, 2035

(11 years from now)

US10213572 VERO BIOTECH INC Nitrogen dioxide storage cassette
Feb, 2036

(11 years from now)

US11672938 VERO BIOTECH INC Start-up protocols for nitric oxide delivery device
Jul, 2040

(16 years from now)

Genosyl is owned by Vero Biotech Inc.

Genosyl contains Nitric Oxide.

Genosyl has a total of 25 drug patents out of which 1 drug patent has expired.

Expired drug patents of Genosyl are:

  • US6758214

Genosyl was authorised for market use on 20 December, 2019.

Genosyl is available in gas;inhalation dosage forms.

Genosyl can be used as a method of delivering nitric oxide to a patient, a method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia.

The generics of Genosyl are possible to be released after 22 July, 2040.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient; A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents